Pliant Therapeutics (NASDAQ:PLRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Pliant Therapeutics (NASDAQ:PLRX) from a sell rating to a hold rating in a research report report published on Sunday.

Other analysts also recently issued research reports about the company. JPMorgan Chase & Co. reissued an “underweight” rating on shares of Pliant Therapeutics in a research note on Friday, October 10th. Weiss Ratings restated a “sell (e+)” rating on shares of Pliant Therapeutics in a report on Wednesday, October 8th. Citigroup restated a “neutral” rating on shares of Pliant Therapeutics in a research report on Sunday, August 10th. Finally, Piper Sandler decreased their price target on Pliant Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research report on Friday, August 8th. One research analyst has rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Pliant Therapeutics currently has an average rating of “Reduce” and an average target price of $3.93.

Pliant Therapeutics Stock Down 4.8%

PLRX opened at $1.57 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.94 and a quick ratio of 13.93. Pliant Therapeutics has a 12 month low of $1.10 and a 12 month high of $15.80. The stock’s 50 day moving average price is $1.60 and its 200 day moving average price is $1.51. The stock has a market cap of $96.47 million, a P/E ratio of -0.55 and a beta of 1.41.

Pliant Therapeutics (NASDAQ:PLRX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.10. As a group, research analysts predict that Pliant Therapeutics will post -3.64 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. American Century Companies Inc. grew its holdings in shares of Pliant Therapeutics by 9.2% during the 1st quarter. American Century Companies Inc. now owns 110,093 shares of the company’s stock valued at $149,000 after acquiring an additional 9,244 shares in the last quarter. Rangeley Capital LLC grew its stake in shares of Pliant Therapeutics by 20.4% in the 2nd quarter. Rangeley Capital LLC now owns 60,220 shares of the company’s stock valued at $70,000 after buying an additional 10,220 shares in the last quarter. Algert Global LLC increased its holdings in Pliant Therapeutics by 17.7% in the third quarter. Algert Global LLC now owns 104,382 shares of the company’s stock worth $154,000 after buying an additional 15,692 shares during the last quarter. Engineers Gate Manager LP grew its position in Pliant Therapeutics by 139.4% in the second quarter. Engineers Gate Manager LP now owns 31,423 shares of the company’s stock worth $36,000 after acquiring an additional 18,300 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its stake in shares of Pliant Therapeutics by 119.1% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 35,540 shares of the company’s stock worth $41,000 after purchasing an additional 19,320 shares during the last quarter. 97.30% of the stock is owned by hedge funds and other institutional investors.

About Pliant Therapeutics

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.